Skip to main content
Back to feed
HealthReportedLow
2.1

FDA expands Olumiant approval to pediatric alopecia patients

Eli Lilly received expanded FDA approval for Olumiant to treat severe alopecia areata in patients aged 12 and older. This extends the drug's indication from adults to adolescents, potentially broadening the patient population. The move is a regulatory milestone for Lilly but does not alter the competitive landscape significantly.

Valor Econômicoabout 24 hours agoUSCredibility 43%View source

Score Breakdown

Mosaic Score2.1
Model confidence0.9
Significance0.1
Source credibility0.4

Intelligence Tags

#fda#drug-approval#alopecia#eli-lilly#pharmaceuticals

Locations

Washington, D.C.

Entities

country
Source

Related signals

8 found